vida: extract claims from 2026-04-22-kff-poll-1-in-8-glp1-affordability-gap

- Source: inbox/queue/2026-04-22-kff-poll-1-in-8-glp1-affordability-gap.md
- Domain: health
- Claims: 0, Entities: 0
- Enrichments: 4
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level.md

@@ -16,3 +16,10 @@ related: ["generic-digital-health-deployment-reproduces-existing-disparities-by-
 # Federal GLP-1 expansion programs reproduce the access hierarchy at the program design level, not just through market dynamics
 
 The Medicare GLP-1 Bridge program demonstrates that the GLP-1 access inversion operates at the program design level, not just the market level. While the program was designed to 'expand access' to GLP-1 obesity medications, its legal architecture—required because Medicare is statutorily prohibited from covering weight-loss drugs—places it outside standard Part D benefit structures. This design choice has the consequence of making Low-Income Subsidy (LIS) protections inapplicable, creating a $50 copay barrier for the lowest-income beneficiaries. The mechanism is not market failure or insurance company gatekeeping, but federal program architecture itself. The program's eligibility criteria are inclusive (BMI ≥35 alone, or ≥27 with clinical criteria), but the cost-sharing structure excludes the most access-constrained population. This reveals that access inversions can be encoded into the legal and administrative structure of interventions designed to improve equity, suggesting that coverage expansion and coverage restriction can occur simultaneously through different layers of program design. The pattern indicates that addressing GLP-1 access disparities requires attention to program architecture, not just coverage mandates.
+
+
+## Supporting Evidence
+
+**Source:** KFF 2025 poll demographic breakdown
+
+Age 65+ adults show only 9% GLP-1 usage compared to 22% for ages 50-64, directly reflecting Medicare's statutory exclusion of weight-loss drugs. This creates a sharp discontinuity at the Medicare eligibility threshold despite this population having the highest obesity burden and worst health outcomes. The demographic pattern confirms that structural coverage exclusions, not clinical need, determine access.

domains/health/glp-1-access-structure-inverts-need-creating-equity-paradox.md

@@ -39,3 +39,10 @@ The Medicaid population has the highest obesity burden (40% of adults, 25% of ch
 **Source:** KFF analysis of Medicare GLP-1 Bridge program (April 2026)
 
 The Medicare GLP-1 Bridge program provides concrete evidence that the access inversion operates through federal program architecture, not just market dynamics. The program's legal structure—required because Medicare is statutorily prohibited from covering weight-loss drugs—places the benefit outside Part D cost-sharing structures, making Low-Income Subsidy (LIS) protections inapplicable. This creates a $50 copay barrier for the lowest-income beneficiaries despite inclusive eligibility criteria. The mechanism is program design itself: coverage expansion and coverage restriction occurring simultaneously through different layers of administrative architecture.
+
+
+## Supporting Evidence
+
+**Source:** KFF 2025 national poll, N=1,309 adults
+
+KFF national poll finds only 23% of obese/overweight adults currently taking GLP-1s, meaning 77% of the eligible population is not accessing treatment despite drug availability. Among current users, 56% report difficulty affording medications, and 27% of insured users paid full cost out-of-pocket. Cost-driven discontinuation (14%) rivals side effect discontinuation (13%), demonstrating affordability as a primary access barrier.

domains/health/glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost.md

@@ -32,3 +32,10 @@ As of January 2026, only 13 states (26% of state programs) cover GLP-1s for obes
 **Source:** KFF analysis of Medicare GLP-1 Bridge program (April 2026)
 
 The Medicare GLP-1 Bridge program demonstrates that access inversion operates at the federal program design level, not just state-level coverage decisions. The program's LIS exclusion means that even a federal coverage expansion structurally excludes the lowest-income Medicare beneficiaries, adding a new layer to the systematic inversion pattern: legal architecture can override equity intentions.
+
+
+## Supporting Evidence
+
+**Source:** KFF 2025 poll condition-specific usage
+
+Among patients with diagnosed conditions showing clear clinical benefit, uptake remains limited: 45% of diabetes patients and 29% of heart disease patients currently using GLP-1s. Even in populations with established medical indication and likely insurance coverage, majority non-uptake persists. The 56% affordability difficulty rate among current users demonstrates cost barriers operate even after initial access is achieved.

domains/health/glp1-long-term-persistence-ceiling-14-percent-year-two.md

@@ -10,14 +10,16 @@ agent: vida
 scope: structural
 sourcer: BCBS Health Institute
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[AI middleware bridges consumer wearable data to clinical utility because continuous data is too voluminous for direct clinician review]]"]
-related:
-- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation
-- GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management
-reweave_edges:
-- glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation|related|2026-04-09
-- GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management|related|2026-04-09
+related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x", "divergence-glp1-economics-chronic-cost-vs-low-persistence"]
+reweave_edges: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation|related|2026-04-09", "GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management|related|2026-04-09"]
 ---
 
 # GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements
 
-Despite the near-doubling of year-one persistence rates, Prime Therapeutics data shows only 14% of members newly initiating a GLP-1 for obesity without diabetes were persistent at two years (1 in 7). Three-year data from earlier cohorts shows further decline to approximately 8-10%. The striking divergence between year-one persistence (62.7% for semaglutide in 2024) and year-two persistence (14%) suggests that the drivers of short-term adherence improvement—supply access, initial motivation, dose titration support—are fundamentally different from the drivers of long-term dropout. This creates a structural ceiling on long-term adherence under current support infrastructure. The mechanisms that successfully doubled year-one persistence (supply normalization, improved patient management) do not translate to sustained behavior change, suggesting that continuous monitoring, behavioral support, or different care delivery models may be required to address the long-term adherence problem. This persistence ceiling is the specific mechanism by which the population-level mortality signal from GLP-1 therapy gets delayed despite widespread adoption.
+Despite the near-doubling of year-one persistence rates, Prime Therapeutics data shows only 14% of members newly initiating a GLP-1 for obesity without diabetes were persistent at two years (1 in 7). Three-year data from earlier cohorts shows further decline to approximately 8-10%. The striking divergence between year-one persistence (62.7% for semaglutide in 2024) and year-two persistence (14%) suggests that the drivers of short-term adherence improvement—supply access, initial motivation, dose titration support—are fundamentally different from the drivers of long-term dropout. This creates a structural ceiling on long-term adherence under current support infrastructure. The mechanisms that successfully doubled year-one persistence (supply normalization, improved patient management) do not translate to sustained behavior change, suggesting that continuous monitoring, behavioral support, or different care delivery models may be required to address the long-term adherence problem. This persistence ceiling is the specific mechanism by which the population-level mortality signal from GLP-1 therapy gets delayed despite widespread adoption.
+
+## Extending Evidence
+
+**Source:** KFF 2025 poll
+
+Cost is a major driver of discontinuation: 14% of former GLP-1 users stopped due to cost, matching the 13% who stopped due to side effects. Among current users, 56% report difficulty affording medications, suggesting cost pressure operates throughout the treatment duration, not just at initiation. The 27% of insured users paying full out-of-pocket cost indicates insurance coverage gaps contribute to persistence failures.